The establishment of EVISA is funded by the EU through
the Fifth Framework Programme (G7RT- CT- 2002- 05112).
Supporters of EVISA includes:
Glossary
iron dextran complex
A colloidal solution containing ferric oxyhydroxide complexed with
polymerized dextran, used as a form of parenteral iron-replacement
therapy. Upon administration and absorption, the iron dextran complex is
removed from plasma by the reticuloendothelial system which cleaves it
into the components iron and dextran; ferric iron subsequently binds to
transferrin or is stored as hemosiderin or ferritin. Transferrin-bound
iron is transported in the plasma to the liver, spleen and bone marrow,
where is it is incorporated into hemoglobin (Hgb) and to muscle where it
is incorporated into myoglobin (Mb). Use of this agent circumvents the
gastrointestinal adverse effects commonly encountered with the use of
orally administered iron salt preparations. Because of cross-reactivity with antibodies targeted against
polysaccharides similar to dextran, anaphylactic reactions may occur with
this type of iron formulation.